Retroviral Vectors: From Laboratory Tools to Molecular Medicines

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 5, Issue 2, 1996, Pages 139-158

  Vile, Richard G ^a   Tuszynski, Anna ^a   Castleden, Simon ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Gene therapy; Gene transfer; Retroviral vectors; Retroviruses

Indexed keywords

UNIDENTIFIED RETROVIRUS;

ANIMAL; CLASSIFICATION; CLINICAL TRIAL; FORECASTING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; RETROVIRUS; REVIEW; ULTRASTRUCTURE;

ANIMALS; CLINICAL TRIALS; FORECASTING; GENE THERAPY; GENETIC VECTORS; HUMANS; RETROVIRIDAE;

EID: 0030124776     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02789062     Document Type: Review

References (115)

1. Mann, R. M., Mulligan, R. C., and Baltimore, D. (1983) Construction of a retro virus packaging mutant and its use to produce helper free defective retrovirus. Cell 33, 149-153.
2. Weiss, R. A., Teich, N., Varmus, H. E., and Coffin, J. (1982) 1985) Molecular Biology of KNA Tumor Viruses, vols. 1 and 2. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
3. Panganiban, A. T. and Fiore, D. (1988) Ordered interstrand and intrastrand DNA transfer during reverse transcription. Science 241, 1064-1069.
4. Vile, R. G. (1991) The retroviral tile cycle and the molecular construction of retrovirus vectors, in Practical Molecular Virology: Viral Vectors for Gene Expression (Collins, M. K. L., ed.), Humana Press, Totowa, NJ, pp. 1-16.
5. Whitcomb, J. M. and Hughes, S. H. (1992) Retroviral reverse transcription and integration: progress and problems. Annu. Rev. Cell Biol. 8, 275-306.
6. Shih, C. C., Stoye, J. P., and Coffin, J. M. (1988) Highly preferred targets for retrovirus integration. Cell 53, 531-537.
7. Mooslehner, K., Karls, U., and Harbors, K. (1990) Retroviral integration sites in transgenic mice frequently map in the vicinity of transcribed DNA regions. J. Virol. 64, 3056-3058.
8. Varmus, H. E. (1988) Retroviruses. Science 240, 1427-1435.
9. Miller, A. D. (1992) Retroviral vectors. Curr. Top. Microbiol. Immunol. 158, 1-24.
10. Bender, M. A., Palmer, T. D., Gelinas, R. E., and Miller, A. D. (1987) Evidence that the packaging sequence of Moloney murine leukemia virus extends into the gag region. J. Virol. 61, 1639-1646.
11. Morgenstern, J. P. and Land, H. (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596.
12. Panganiban, A. T. and Varmus, H. M. (1983) The terminal nucleotides of retrovirus DNA are required for integration but not virus production. Nature 306, 155-160.
13. Miller, D. G., Adam, M. A., and Miller, A. D. (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10, 4239-4242.
14. Lewis, P. F. and Emerman, M. (1993) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68, 510-516.
15. Overell, R. W., Weisser, K. E., and Cosman, D. (1988) Stably transmitted triple-promoter retroviral vectors and their use in transformation of primary mammalian cells. Mol. Cell. Biol. 8, 1803-1808.
16. Vile, R. G., Miller, N., Chernajovsky, Y., and Hart, I. R. (1994) A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1, 307-316.
17. Hantzopoulos, P. A., Sullenger, B. A., Ungers, G., and Gilboa, E. (1989) Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc. Natl. Acad. Sci. USA 86, 3519-3523.
18. Mulligan, R. C. (1993) The basic science of gene therapy. Science 260, 926-932.
19. Stoker, A., ed. (1993) Retroviral vectors, in Molecular Virology: A Practical Approach. IRL, Oxford, pp. 172-197.
20. Vile, R. G. and Russell, S. J. (1995) Retroviruses as vectors. Br. Med. Bull. 51, 12-30.
21. Miller, A. D. (1990) Retrovirus packaging cells. Hum. Gene Ther. 1, 5-14.
22. Vile, R. G. (1991) Selectable markers for eukaryotic cells, in Practical Molecular Virology: Viral Vectors for Gene Expression (Collins, M. K. L., ed.), Humana, Totowa, NJ, pp. 49-60.
23. Price, J., Turner, D., and Cepko, C. (1987) Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 84, 156-160.
24. Von Melchner, H. and Ruley, H. E. (1989) Identification of cellular promoters by using a retrovirus promoter trap. J. Virol. 63, 3227-3233.
25. Lu, S. J., Man, S., Bani, M. R., Adachi, D., Hawley, R. G., Kerbel, R. S., and Ben-David, Y. (1995) Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamine-dichloroplatinum(II) resistance. Cancer Res. 55, 1139-1145.
26. Miller, A. D. (1992) Human gene therapy cornes of age. Nature 357, 455-460.
27. Miller, A. D. and Buttimore, C. (1986) Redesign of retrovirus packaging cell line to avoid recombination leading to helper virus formation. Mol. Cell. Biol. 6, 2895-2902.
28. Rosenberg, S. A., Aebersold, P., and Cornetta, K. (1990) Gene transfer into humans-immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570-578.
29. Ram, Z., et al. (15193) Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurg. 79, 400-407.
30. Danos, O. and Mulligan, R. C. (1988) Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host range. Proc. Natl. Acad. Sci. USA 85, 6460-6464.
31. Markowitz, D., Goff, S., and Bank, A. (1988) A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62, 1120-1124.
32. Bosselman, R. A., Hsu, R. Y., Bruszewski, J., Hu, S., Martin, F., and Nicolson, M. (1987) Replication defective chimeric helper proviruses and factors affecting generation of competent virus: expression of Moloney murine leukemia virus structural genes via the metallothionein promoter. Mol. Cell. Biol. 7, 1797-1806.
33. Dougherty, J. P., Wisniewski, R., Yang, S., Rhode, B. W., and Temin, H. M. (1989) New retrovirus helper cells with almost no nucleotide homology to retroviral vectors. J. Virol. 63, 3209-3212.
34. Takahara, Y., Hamada, K., and Housman, D. E. (1992) A new retrovirus packaging cell for gene transfer constructed from amplified long terminal repeat-free chimeric proviral genes. J. Virol. 66, 3725-3732.
35. Muenchau, D. D., Freeman, S. M., Cornatta, K., Zwiebel, J. A., and Anderson, W. F. (1990) Analysis of retroviral packaging lines for generation of replication-competent virus. Virology 176, 262-265.
36. Scadden, D. T., Fullers B., and Cunningham, J. M. (1990) Human cells infected with retrovirus vectors acquire an endogenous murine provirus. J. Virol. 64, 424-427.
37. Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., and Dunbar, C. (1992) Helper virus induced T cell lymphoma in non human primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125-1135.
38. Anderson, W. F. (1993) What about those monkeys that got T-cell lymphoma? Hum. Gene Ther. 4, 1,2.
39. Cornetta, K., et al. (1990) Amphotropic murine leukaemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1, 15-30.
40. Cornetta, K., et al. (1991) No retroviremia or pathology in long-term follow up of monkeys exposed to a murine amphotropic retrovirus. Hum. Gene Ther. 2, 215-219.
41. Cornetta, K. (1992) Safety aspects of gene therapy. Br. J. Haematol. 80, 421-426.
42. Moolten, F. L. and Cupples, L. A. (1992) A model for predicting the risk of cancer consequent to retroviral gene therapy. Hum. Gene Ther. 3, 479-486.
43. Yee, J. K., Moores, J. C., Jolly, D. J., Wolff, J. A., Respress, J. G., and Friedmann, T. (1987) Gene expression from transcriptionally disabled retroviral vectors. Proc. Natl. Acad. Sci. USA 84, 5197-5201.
44. Welsh, R. M., Cooper, N. R., Jensen, F. C., and Oldstone, M. B. A. (1975) Human serum lyses RNA tumour viruses. Nature 257, 612-614.
45. Takeuchi, Y., Cosset, F. L., Lachmann, P. J., Okada, H., Weiss, R. A., and Collins, M. K. L. (1994) Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68, 8001-8007.
46. Varela-Echavarria, A., Prorock, C. M., Ron, Y., and Dougherty, J. P. (1993) High rate of genetic rearrangement during replication of a Moloney Murine Leukemia virus-based vector. J. Virol. 67, 6357-6364.
47. Dougherty, J. P. and Temin, H. M. (1986) High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol. Cell. Biol. 6, 4387-4395.
48. Fujiwara, T., Cai, D. W., Georges, R. N., Mukhopadhyay, T., Grimm, E. A., and Roth, J. A. (1994) Therapeutic effects of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Nad. Cancer Inst. 86, 1458-1462.
49. Jaffee, E. M., Dranoff, G., Cohen, L. K., Hauda, K. M., Clift, S., Marshall, F. F., Mulligan, R. C., and Pardoll, D. M. (1993) High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. 53, 2221-2226.
50. Bestwick, R. K., Kozak, S. L., and Kabat, D. (1988) Overcoming interference to retroviral super infection results in amplified expression and transmission of cloned genes. Proc. Natl. Acad. Sci. USA 85, 5404-5408.
51. Landau, N. R. and Liftman, D. R. (1992) Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J. Virol. 66, 5110-5113.
52. Weiss, R. A. (1993) Cellular receptors and viral glycoproteins involved in retrovirus entry, in The Retroviridae, vol. 2 (Levy, J., ed.), Plenum, New York, pp. 1-108.
53. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90, 8033-8037.
54. Richards, C. A. and Huber, B. E. (1993) Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum. Gene Ther. 4, 143-150.
55. Palmer, T. D., Rosman, G. J., Osborne, W. R. A., and Miller, A. D. (1991) Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88, 1330-1334.
56. Russell, S. J., Eccles, S. A., Flemming, C. L., Johnson, C. A., and Collins, M. K. L. (1991) Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer 47, 244-251.
57. Gansbacher, B., Houghton, A., Livingston, P., Minasian, L., Rosenthal, F., Gilboa, E., Golde, D., Oettgen, H., Steffans, T., Yang, S. Y., and Wong, G. (1992) Clinical Protocol: a pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum. Gene Ther. 3, 677-690.
58. Dranoff, G., et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting antitumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
59. Petropoulos, C. J., Payne, W., Salter, D. W., and Hughes, S. H. (1992) Using avian retroviral vectors for gene transfer. J. Virol. 66, 3391-3397.
60. Scharfmann, R., Axelrod, J. H., and Verma, I. M. (1991) Long term in vivo expression of retrovirus mediated gene transfer in mouse fibroblast implants. Proc. Natl. Acad. Sci. USA 88, 4626-4530.
61. Li, M., Hantzopoulos, M. L. P. A., Banerjee, D., Schweitzer, B. I., Gilboa, E., and Bertino, J. R. (1992) Comparison of the expression of a mutant dihydrofolate reductase gene under control of different internal promoters in retroviral vectors. Hum. Gene Ther. 3, 381-390.
62. Emerman, M. and Temin, H. M. 1984) Genes with promoters in retroviral vectors can be independently suppressed by an epigenic mechanism. Cell 39, 459-467.
63. Salmons, B. and Gunzburg, W. H. (1993) Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4, 129-141.
64. Soriano, P., Friedrich, G., and Lawinger, P. (1991) Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells. J. Virol. 2314-2313.
65. Morgan, R. A., Couture, L., Elroy-Stein, O., Ragheb, J., Moss, B., and French Anderson, W. (1992) Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20, 1293-1299.
66. Adam, M. A., Ramesh, N., Dusty Miller, A., and Osborne, W. R. A. (1991) Internal initiation of translation in retroviral vectors carrying picornavirus 5′ nontranslated regions. J. Virol. 65, 4985-4990.
67. Koo, H., Brown, A. M. C., Kaufman, R. J., Prorock, C. M., Ron, Y., and Dougherty, J. P. (1992) A spleen necrosis virus-based retroviral vector which expresses two genes from a dicistronic mRNA. Virology 186, 669-675.
68. Boris-Lawrie, K. A. and Temin, H. M. (1993) Recent advances in retrovirus vector technology. Curr. Opin. Gene. Dev. 3, 102-109.
69. Oldfield, E. H., et al. (1993) Clinical Protocol: gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69.
70. Friedmann, T. (1992) Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70(Suppl.), 1810-1817.
71. Collins, F. S. (1992) Cystic fibrosis: molecular biology and therapeutic implications. Science 256, 774-779.
72. Vile, R. G. and Russell, S. J. (1994) Gene transfer technologies for the gene therapy of cancer. Gene Ther. 1, 88-98.
73. Miller, D. G., Edwards, R. H., and Miller, A. D. (1994) Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc. Natl. Acad. Sci. USA 91, 78-82.
74. Battini, J. L., Heard, J. M., and Danos, O. (1992) Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic and polytropic murine leukemia viruses. J. Virol. 66, 1468-1475.
75. Morgan, R. A., Nussbaum, O., Muenchau, D. D., Shu, L., Couture, L., and French Anderson, W. (1993) Analysis of the functional and host range-determining regions of the murine ecotropic and amphotropic retrovirus envelope proteins. J. Virol. 67, 4712-4721.
76. Ott, D. and Rein, A. (1992) Basis for receptor specificity of nonecotropic murine leukemis virus surface glycoprotein gp70SU. J. Virol. 66, 4632-4638.
77. Dong, J., Roth, M. G., and Hunter, E. (1992) A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J. Virol. 66, 7374-7382.
78. Roux, P., Jeanteur, P., and Piechaczyk, M. (1989) A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc. Natl. Acad. Sci. USA 86, 9079-9083.
79. Russell, S. J., Hawkins, R. E., and Winter, G. (1993) Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21, 1081-1085.
80. Young, J. A. T., Bates, P., Willert, K., and Varnous, H. E. (1990) Efficient incorporation of human CD4 protein into Avian Leukosis Virus particles. Science 250, 1421.
81. Etienne-Julan, M., Roux, P., Carillo, S., Jeanteur, P., and Piechaczyk, M. (1992) The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J. General Virol. 73, 3251-3255.
82. Cosset, F. L., Ronfort, C., Molina, R. M., Flamant, F., Drynda, A., Benchaibi, M., Valesia, S., Nigon, V. M., and Verdier, G. (1992) Packaging cells foravian leukosis virus-based vectors with various host ranges. J. Virol. 66, 5671-5676.
83. Van der Bruggen, P. and Van den Eynde, B. (1992) Molecular definition of tumor antigens recognized by T-lymphocytes. Curr. Opin. Immunol. 4, 608-612.
84. Vile, R. G. (1994) Tumour specific gene expression. Semin. Cancer Biol. 5, 429-436.
85. Dillon, N. (1993) Regulating gene expression in gene therapy. Trends Biotechnol. 11, 167-173.
86. Dzierzak, E. A., Papayannopoulou, T., and Mulligan, R. C. (1988) Lineage specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 331, 3541.
87. Hatzoglou, M., Bosch, F., Park, E. A., and Hanson, R. W. (1990) Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase. J. Biol. Chem. 265, 17,285-17,293.
88. Hatzoglou, M., Bosch, F., Park, E. A., and Hanson, R. W. (1991) Hormonal control of interacting promoters introduced into cells by retroviruses. J. Biolog. Chem. 266, 8416-8425.
89. Harris, J. D., Gutierrez, A. A., Hurst, H. C., Sikora, K., and Lemoine, N. R. (1994) Gene therapy for carcinoma using tumour-specific prodrug activation. Gene Ther. 1, 170-175.
90. Huber, B. E., Richards, C. A., and Krenitsky, T. A. (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88, 8039-8043.
91. Anderson, W. F. (1992) Human Gene therapy. Science 256, 808-813.
92. Rosenberg, S. A., French Anderson, W., Blaese, M., Hwu, P., Yannelli, J. R., Yang, J. C., Topalian, S., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., Parkinson, D. N., and White, D. E. (1993) The development of gene therapy for the treatment of cancer. Ann. Surg. 218, 455-464.
93. Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., and Blaese, R. M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
94. Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., and Oldfield, E. H. (1993) In situ retroviral mediated gene transfer for the treatment of brain tumours in rats. Cancer Res. 53, 83-88.
95. Georges, R. N., Mukhopadhyay, T., Zhang, Y., Yen, N., and Roth, J. A. (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53, 1743-1746.
96. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Cai, D. E., Owen-Schaub, L. B., and Roth, J. A. (1993) A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53, 4129-4133.
97. Whartenby, K. A., Abboud, C. N., Marrogi, A. J., Ramesh, R., and Freeman, S. M. (1995) The biology of cancer gene therapy. Lab. Invest. 72, 131-145.
98. Alton, E. W. F. W, Middleton, P. G., Caplen, N. J., Smith, S. N., Steel, D. M., Munkonge, F. M., Jeffery, P, K., Geddes, D. M., Hart, S. L., Williamson, R., and Fasold, K. I. (1993) Non-invasive liposome-mediated gene delivery can correct the ion transport detect in cystic fibrosis mutant mice. Nature Gene. 5, 135-142.
99. Hyde, S. C., Gill, D. R., Higgins, C. F., Trezise, A. E. O., MacVinish, L. J., Cuthbert, A. W., Ratclif, R., Evans, M. J., and Colledge, W. H. (1993) Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362, 250-255.
100. Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A. E., and Welsh, M. J. (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75, 207-216.
101. Nabel, G. J., Chang, A., Nabel, E. G., Plautz, G., Fox, B. A., Huang, L., and Shu, S. (1992) Clinical Protocol: immunotherapy of malignancy by in vivo gene transfer into tumors. Hum. Gene Ther. 3, 399-410.
102. Kim, T. S., Russell, S. J., Collins, M. K. L., and Cohen, E. P. (1992) Immunity to B16 melanoma in mice immunized with IL-2 secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int. J. Cancer 51, 283-289.
103. Flugel, R. M. (1991) Spumaviruses: a group of complex retroviruses. J. Acquired Immune Defic. Syndromes 4, 739-750.
104. Vile, R. G., Ali, M., Hunter, E., and McClure, M. O. (1992) Identification of a generalised packaging sequence for D-type retroviruses and generation of a D-type retroviral vector. Virology 189, 786-791.
105. Gilboa, E. and Smith, C. (1994) Gene therapy for infectious diseases: the AIDS model. Trends Gene. 10, 109-114.
106. Brady, H. J. M., Miles, C. G., Pennington, D. J., and Dzierzak, E. A. (1994) Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc. Natl. Acad. Sci. USA 91, 365-369.
107. Buchschacher, G. L. and Panganiban, A. T. (1992) Human immunodeficiency virus vectors for inducible expression of foreign genes. J. Virol. 66, 2731-2739.
108. Bukrinsky, M. I., Haggerty, S., Dempsey, M. P., Sharova, N., Adzhubel, A., Spitz, L., Lewis, P., Goldfarb, D., Emerman, M., and Stevenson, M. (1993) A nuclear localisation signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365, 666-669.
109. Russell, S. J. (1993) Gene therapy for cancer. Cancer J. 6, 21-25.
110. Russell, S. J. (1994) Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol. 5, 437-443.
111. Dupressoir, T., Vanacker, J. M., Cornells, J. J., Duponchel, N., and Rommelaere, J. (1989) Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res. 49, 3203-3208.
112. Asada, T. (1974) Treatment of human cancer with mumps virus. Cancer 34, 1907-1928.
113. Southam, C. M. (1960) Present status of oncolytic virus studies. Trans NY Acad. Sci. 22, 657-673.
114. Takamiya, Y., Short, M. P., Ezzeddine, Z. D., Moolten, F. L., Breakefield, X. O., and Martuza, R. L. (1992) Gene therapy of malignant brain tumors: a rat glioma line bearing the Herpes Simplex Virus Type 1-thymidine kinase gene and wild type retrovirus kilts other tumor cells. J. Neurosci. Res. 33, 493-503.
115. Miller, N. and Vile R. G. (1995) Targeted vectors for gene therapy. FASEB J. 9, 190-199.